ReviewJournal of fungi (Basel, Switzerland)2016
Allergic Bronchopulmonary Aspergillosis.
Review in Journal of fungi (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Biologic drugs in treating allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2022Pooled it
- Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Inhaled Voriconazole in Healthy Volunteers and Subjects With Stable Asthma.Pharmacology research & perspectives · 2025Trial
- Suspected allergic bronchopulmonary candidiasis in a patient with concurrent multidrug-resistant bacterial pneumonia: A case report.Medicine · 2026Article
- Protocol for a systematic literature review and network meta-analysis of the evidence for therapies in allergic bronchopulmonary aspergillosis (ABPA).Systematic reviews · 2026Article
- Helminth Immune Modulation and Invasive Fungal Infections in Sub-Saharan Africa.Journal of fungi (Basel, Switzerland) · 2026Article
- Establishment of a novel murine model of allergic bronchopulmonary aspergillosis using an eosinophilic mutant mouse.The Journal of veterinary medical science · 2026Article
- Allergic bronchopulmonary aspergillosis andJournal of thoracic disease · 2025Review
- Development and validation of a clinical prediction model forFrontiers in medicine · 2025Article
- Eosinophilic Granulomatous Polyangiitis with Autoimmune Hemolytic Anemia: A Case Report and Review of the Literature.Journal of asthma and allergy · 2025Article
- Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators.Journal of fungi (Basel, Switzerland) · 2024Review
- Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment.Biomedicines · 2024Review
- Occupational Lung Disease Causing Allergic Bronchopulmonary Aspergillosis: A Case Report.Cureus · 2024Article
- Serum Cytokine Changes in a Patient with Chronic Pulmonary Aspergillosis Overlapping with Allergic Bronchopulmonary Aspergillosis.Internal medicine (Tokyo, Japan) · 2024Article
- Pathogenicity and virulence ofVirulence · 2023Review
- Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals.Journal of fungi (Basel, Switzerland) · 2023Article
- Higher risk for influenza-associated pulmonary aspergillosis (IAPA) in asthmatic patients: A Swiss multicenter cohort study on IAPA in critically ill influenza patients.Influenza and other respiratory viruses · 2023Article
- Pulmonary aspergillosis: diagnosis and treatment.European respiratory review : an official journal of the European Respiratory Society · 2022Article
- Occurrence of Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutations in Patients with Allergic Bronchopulmonary Aspergillosis Complicating Asthma.Mycopathologia · 2022Article
- Serum Cytokines Usefulness for Understanding the Pathology in Allergic Bronchopulmonary Aspergillosis and Chronic Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2022Article
- Characterising the allergic profile of children with cystic fibrosis.Immunity, inflammation and disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic bronchopulmonary aspergillosis (ABPA), a progressive fungal allergic lung disease, is a common complication of asthma or cystic fibrosis. Although ABPA has been recognized since the 1950s, recent research has underscored the importance of Th2 immune deviation and granulocyte activation in its pathogenesis. There is also strong evidence of widespread under-diagnosis due to the complexity and lack of standardization of diagnostic criteria. Treatment has long focused on downregulation of the inflammatory response with prolonged courses of oral glucocorticosteroids, but more recently concerns with steroid toxicity and availability of new treatment modalities has led to trials of oral azoles, inhaled amphotericin, pulse intravenous steroids, and subcutaneously-injected anti-IgE monoclonal antibody omalizumab, all of which show evidence of efficacy and reduced toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.